Two novel atypical PKC inhibitors; ACPD and DNDA effectively mitigate cell proliferation and epithelial to mesenchymal transition of metastatic melanoma while inducing apoptosis WS Ratnayake, AH Apostolatos, DA Ostrov, M Acevedo-Duncan International Journal of Oncology 51 (5), 1370-1382, 2017 | 36 | 2017 |
Oncogenic PKC-ι activates Vimentin during epithelial-mesenchymal transition in melanoma; a study based on PKC-ι and PKC-ζ specific inhibitors WS Ratnayake, CA Apostolatos, AH Apostolatos, RJ Schutte, MA Huynh, ... Cell adhesion & migration 12 (5), 447-463, 2018 | 32 | 2018 |
Inhibition of atypical protein kinase C‑ι effectively reduces the malignancy of prostate cancer cells by downregulating the NF-κB signaling cascade AH Apostolatos, WS Ratnayake, H Win-Piazza, CA Apostolatos, ... International Journal of Oncology 53 (5), 1836-1846, 2018 | 25 | 2018 |
Atypical PKCs activate Vimentin to facilitate prostate cancer cell motility and invasion WS Ratnayake, CA Apostolatos, S Breedy, CL Dennison, R Hill, ... Cell Adhesion & Migration 15 (1), 37-57, 2021 | 16 | 2021 |
FOXO1 regulates oncogenic PKC-ι expression in melanoma inversely to c-Jun in an autocrine manner via IL-17E and ICAM-1 activation WS Ratnayke, CA Apostolatos, S Breedy, AH Apostolatos, ... World Academy of Sciences Journal 1 (1), 25-38, 2019 | 9 | 2019 |
Preclinical testing of 5-amino-1-((1R, 2S, 3S, 4R)-2, 3-dihydroxy-4-methylcyclopentyl)-1H-imidazole-4-carboxamide: A potent protein kinase C-ι inhibitor as a potential prostate … AH Apostolatos, CA Apostolatos, WS Ratnayake, A Neuger, S Sansil, ... Anti-Cancer Drugs 30 (1), 65-71, 2019 | 8 | 2019 |
Atypical protein kinase c inhibitors can repress epithelial to mesenchymal transition (type III) in malignant melanoma WS Ratnayake, M Acevedo-Duncan Cancer Research 77 (13_Supplement), 862-862, 2017 | 8 | 2017 |
Use of ACPD and ICA-1 as inhibitors of atypical proteinkinase C-zeta (ζ) and iota (ι) in metastasized melanoma cells WS Ratnayake, M Acevedo-Duncan Cancer Research 76 (14_Supplement), 4569-4569, 2016 | 7 | 2016 |
Atypical protein kinase Cs in melanoma progression WS Ratnayake, CA Apostolatos, M Acevedo-Duncan Cutan Melanoma, 2019 | 3 | 2019 |
Transcription activators that regulate PKC-iota expression and are downstream targets of PKC-iota AH Apostolatos, WS Ratnayake, T Smalley, A Islam, M Acevedo-Duncan Cancer Research 77 (13_Supplement), 2369-2369, 2017 | 3 | 2017 |
Method of treating melanoma using an inhibitor of an atypical protein kinase C ME Acevedo-Duncan, W Ratnayake, DA Ostrov US Patent 10,918,650, 2021 | 2 | 2021 |
c‑Jun and FOXO1 mediate the expression of oncogenic PKC‑ι in human prostate cancer cells with an interplay between NF‑κB, IL‑8 and ICAM‑1 MAD Wishrawana S. Ratnayake, Christopher A. Apostolatos, Sloan Breedy World Academy of Sciences Journal 2 (5), 2020 | 2 | 2020 |
Vimentin is a novel PKC-ι target facilitating migration and invasion in melanoma WS Ratnayake, S Breedy, C Apostolatos, R Hill, C Dennison, ... Cancer Research 79 (13_Supplement), 2857-2857, 2019 | 2 | 2019 |
Role of oncogenic protein kinase C-iota in melanoma progression; a study based on atypical protein kinase-C inhibitors WSB Ratnayake University of South Florida, 2019 | 2 | 2019 |
14-3-3 and Smad2/3 are crucial mediators of atypical-PKCs: Implications for neuroblastoma progression S Breedy, WS Ratnayake, L Lajmi, R Hill, M Acevedo-Duncan Frontiers in Oncology 13, 1051516, 2023 | 1 | 2023 |
Dual inhibition of atypical PKC signaling and PI3K/Akt signaling dysregulates c-Myc to induce apoptosis in clear cell Renal Cell Carcinoma KM Khalid, WS Ratnayake, CA Apostolatos, M Acevedo-Duncan Frontiers in Oncology 13, 2023 | 1 | 2023 |
Inhibition of atypical PKC signaling enhances the sensitivity of glioblastoma cells towards Temozolomide therapy A Dey, R Patel, T Smalley, WS Ratnayake, A Islam, M Acevedo-Duncan Cancer Research 79 (13_Supplement), 244-244, 2019 | 1 | 2019 |
PKC-ι and PKC-ζ are heavily responsible of up-regulating epithelial-mesenchymal transition (EMT) and activating Vimentin to facilitate cellular motility in prostate cancer cell … WS Ratnayake, C Apostolatos, S Breedy, R Hill, C Dennison, ... Cancer Research 79 (13_Supplement), 1044-1044, 2019 | 1 | 2019 |
c-Jun and FOXO1 play key roles in the overexpression of oncogenic PKC-ι in human prostate and melanoma cell lines AH Apostolatos, WS Ratnayake, A Islam, C Apostolatos, T Smalley, ... Cancer Research 78 (13_Supplement), 2542-2542, 2018 | 1 | 2018 |
Oncogenic protein kinase Cι drives melanoma cell epithelial-mesenchymal transition by activating vimentin through Par6/RhoA signaling WS Ratnayake, AH Apostolatos, CA Apostolatos, A Dey, R Patel, ... Cancer Research 78 (13_Supplement), 2022-2022, 2018 | 1 | 2018 |